Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. j. infect. dis ; 5(2): 67-72, Apr. 2001. tab
Artigo em Inglês | LILACS | ID: lil-301186

RESUMO

The efficacy and safety of a fixed-dose combination of atovaquone and proguanil hydrochloride (Malarone TM) were compared with chloroquine or pyrimethamine/sulfadoxine in patients with acute falciparum malaria in northern Peru. Patients were initially randomized to receive, 1,000 mg atovaquone and 400 mg mg proguanil hydrochloride daily for 3 days (n=15) or 1,500 mg chloroquine (base) over a 3 day period (n=14) (phase 1). The cure rate with chloroquine was lower than expected and patients were subsequently randomized to receive a single dose of 75 mg pyrimethamine and 1,500 mg sulfadoxine (n=9) or atovaquone/proguanil as before (n=5) (phase 2). In phase 1, atovaquone/proguanil was significantly more effective than chloriquine (cure rate 100 percent [14/14] versus 8 percent [1/13], P<0.0001). In phase 2, atovaquone/proguanil and pyrimethamine/sulfadoxine were both highly effective (cure rates 100 percent [5/5] and 100 percent [7/7]). There were no significant differences between treatment groups in parasite or fever clearance times. Adverse events were typical of malarium symptoms and did not differ significantly between groups. Overall efficacy of atovaquone/proguanil was 100 percent for treatment of acute falciparum malaria in a region with a high prevalence of chloroquine resistance.


Assuntos
Humanos , Adolescente , Adulto , Pessoa de Meia-Idade , Cloroquina , Malária Falciparum , Plasmodium falciparum , Proguanil , Pirimetamina , Sulfadoxina , Doença Aguda , Antimaláricos , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase I como Assunto , Malária Falciparum , Resistência Microbiana a Medicamentos
2.
Southeast Asian J Trop Med Public Health ; 1993 Jun; 24(2): 230-4
Artigo em Inglês | IMSEAR | ID: sea-34384

RESUMO

The clinical results of this study indicate that a half-dose regimen of artesunate followed by mefloquine produces an acceptable cure rate when compared to other commonly available drugs for treating acute uncomplicated falciparum malaria in Thailand. The 90% cure rate was comparable to the results with either a full dose of artesunate (600 mg over 5 days) or mefloquine (25 mg/kg in divided doses six hours apart) as well as the combination of quinine-tetracycline administered for seven days. This abbreviated regimen, however was less effective than the full dose regimen of both drugs previously reported.


Assuntos
Doença Aguda , Adolescente , Adulto , Antimaláricos/administração & dosagem , Artemisininas , Esquema de Medicação , Resistência a Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Malária Falciparum/tratamento farmacológico , Masculino , Mefloquina/administração & dosagem , Pessoa de Meia-Idade , Sesquiterpenos/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA